Extended Data Fig. 6: Molecular effects of duloxetine bioaccumulation.
From: Bioaccumulation of therapeutic drugs by human gut bacteria
a, Alkynated duloxetine made for the biotin-pull down assay. b, Fold change of proteins detected in the duloxetine pull down assay in C. saccharolyticum lysate using alkynated duloxetine. Four replicates were used in both test and control sets. Significantly enriched (hypergeometric test, FDR corrected p < 0.1, log2(Fc)>2) proteins are shown in red. c, d, Bioaccumulating E. coli strain features larger change in protein abundance in response to drug treatment. Shown are the number of proteins with altered abundance in E. coli ED1A (c, non-bioaccumulating), and E. coli IAI1 (d, bioaccumulating) strains in response to duloxetine exposure at different concentrations. e–h, Comparison of MS/MS spectra of four nucleotide-pathway metabolites from the supernatant of duloxetine-treated C. saccharolyticum with MS/MS spectra of analytical standards. (CE = 10 eV; further details in Methods) Related to Fig. 2d and Supplementary Table 11.
